- $183.53m
- $48.61m
- 27
- 42
- 10
- 16
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.864 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0 | 0.2 | 0 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.81 | 32.2 | 63.8 | 51.5 | 78.8 |
Operating Profit | -0.81 | -31.3 | -63.8 | -51.5 | -78.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.81 | -32.2 | -67.6 | -47.5 | -78.1 |
Net Income After Taxes | -0.81 | -32.2 | -67.6 | -47.5 | -78.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.81 | -32.2 | -67.6 | -47.5 | -78.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.81 | -32.2 | -67.6 | -47.5 | -78.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.616 | -11.9 | -15.4 | -9.73 | -9.41 |
Dividends per Share |